NovaBay Pharmaceuticals, Inc. — SEC Form D Filing
NovaBay Pharmaceuticals, Inc. filed an SEC Form D on January 27, 2026, reporting $134.00M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- January 27, 2026
- Amount reported
- $134.00M
- Industry
- Pharmaceuticals
- Headquarters
- EMERYVILLE, California, United States
- Website
- https://novabay.com/
What the company does
Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
People suffer from various unmet medical needs, particularly related to eye and skin health.
Solution
NovaBay Pharmaceuticals develops and sells topical ophthalmic and an-ti-infective products for various health conditions.
Verdict
This cleared because there was an existing market with clear unmet needs in eye and skin health that the science could address, not because of proprietary distribution or a novel business model. Investors were implicitly betting on clinical efficacy and regulatory approval converting into market share within established medical verticals. The upside was limited by the high capital requirements of pharmaceutical development and the established competitive landscape for topical treatments.
Source: SEC EDGAR Form D filing